Screen Reader Mode Icon

Response due: Wednesday, November 30, 2022

The ACTG performance Evaluation Committee conducts a yearly survey of ACTG CRS Leaders to assess the interactions between the CRS and the local Community Advisory Board (CAB). Participation in the survey is required as part of the annual site performance evaluation process. Please note that a separate survey was sent to your site's GCAB Representative earlier in the month.

Instructions for completing the survey:
1. The survey should be completed by each ACTG CRS Leader or his/her designee.
2. Plan to complete the survey in one session.

Should you have any questions, please contact us at PerformanceEvaluation@dlhcorp.com

Question Title

* 1. Provide the name and email address of the CRS Leader or designee

Question Title

* 3. Does this Clinical Research Site (CRS) share its Community Advisory Board (CAB) with another CRS?

Question Title

* 4. Does your CAB also advise another NIAID-funded network (IMPAACT, HVTN, HPTN, or MTN)?

Question Title

* 5. Your CRS ensures that an updated CORE ACTG CAB Handbook is available for use by CAB members and CRS staff. (select one answer below)

Question Title

* 6. Your CRS is supportive of CAB activities and actively engages in the CAB's meetings, trainings, and outreach efforts. (select one answer below)

Question Title

* 7. Your CAB has a process to identify an alternate CAB Representative (non-CRS staff) if the GCAB Representative cannot attend the annual ACTG meeting. (select one answer below)

Question Title

* 8. Your CRS helps as needed if the GCAB Representative has problems arranging travel for the ACTG Meeting. (select one answer below)

Question Title

* 9. Your CRS Staff/CRS Leader routinely provides updates about ACTG clinical trials, including successes and challenges of recruitment/retention, on a regular basis and seeks input from its CAB members concerning these trials. (select one answer below)

Question Title

* 10. How often does your CAB meet? (select one answer below)

Question Title

* 11. Additional Comments (Not Required)

0 of 11 answered
 

T